“…27 gamma-glutamyl transpeptidase (Beuckmann et al, 1995), alkaline phosphatase (Beuckmann et al, 1995), aromatic L-amino acid decarboxylase (Betz et al, 1980;Matter & Balda, 2003b), the phase I metabolising enzymes CYP1A1 (Filbrandt et al, 2004), CYP1B1 (Filbrandt et al, 2004), CYP3A4 (Ghosh et al, 2010;Ghosh et al, 2011), andCyp4x1 (AlAnizy et al, 2006), NADPH-CYP P450 reductase (Chat et al, 1998;Ghersi-Egea et al, 1988;Minn et al, 1991;Ravindranath et al, 1990), epoxide hydrolase (Ghersi-Egea et al, 1988;Minn et al, 1991), and the phase II enzymes, 1-naphthol-UDP-glucuronosyltransferase (Ghersi-Egea et al, 1988) and GSTμ (Shang et al, 2008), and GSTπ (Bauer et al, 2008;Shang et al, 2008). The presence of these enzymes in the brain microvasculature indicates the existence of a metabolic barrier.…”